Peter Zdziarski: Gene Therapy vs Prophylaxis in Glanzmann Thrombasthenia
Peter Zdziarski, Vice President and Marketing Director at the Glanzmann’s Research Foundation, shared a post on LinkedIn:
”Gene Therapy vs Prophylaxis in Glanzmann Thrombasthenia
This is one of the most frequently asked questions I hear from the GT community, and it’s a crucial one.
The distinction matters:
Prophylaxis requires ongoing drug use, often weekly or bi-weekly.
Gene therapy is designed as a single procedure and has the potential for a lasting solution.
What’s important to remember is that both options are still in clinical trials. Marketing to the GT community has put a heavy spotlight on prophylaxis in recent years. For many families, this has made it seem like the only new option, when in fact gene therapy for GT has been in development for years.
That’s why staying informed is so critical. There is meaningful research happening that could change the future of treatment. Both options, and the realities behind them, deserve attention.
If you or a loved one is living with GT, I strongly encourage you to follow the groundbreaking work of Dr. David Wilcox and his team at the Medical College of Wisconsin. Their efforts are bringing real hope for a long-term solution to Glanzmann Thrombasthenia.
Knowledge is power. The more we understand the science, the costs, and the possibilities, the better prepared we are to make the best decisions for our community’s future.”
Find more information here.
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry